Results 141 to 150 of about 545,902 (261)

A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9423-9432, October 2026.
ABSTRACT Aims To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 [500 U/mL]; AT278‐U500) compared with standard concentration insulin aspart (InsAsp [100 U/mL]; InsAsp‐U100) and U500 human regular insulin (HumIns [500 IU/mL]; HumIns‐U500). Materials and Methods This single‐centre, randomised,
Eva Svehlikova, Christina Gatschelhofer, Bettina Lackner, Maria Ratzer, Gabriele Fluhr, Anja Stoisser, Gregor Kolaric, David Gerring, Sarah Howell, Jan Jezek, Fiona Lawrence, Thomas R. Pieber   +11 more
wiley   +1 more source

Targeted analysis of whole exome sequencing in Thai patients with neonatal diabetes. [PDF]

Hum Genet
Plengvidhya N, Tangjarusritaratorn T, Teerawattanapong N, Narkdontri T, Innang S, Songlilitchuwong S, Suthon S, Tangjittipokin W.   +7 more
europepmc   +1 more source

C-type lectin receptors and RIG-I-like receptors: new points on the oncogenomics map

, 2012
Anton G Kutikhin, Arseniy E YuzhalinDepartment of Epidemiology, Kemerovo State Medical Academy, Kemerovo, Russian FederationAbstract: The group of pattern recognition receptors includes families of Toll-like receptors, NOD-like receptors, C-type lectin ...
Yuzhalin AE, Kutikhin AG
core  

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source

The NLRP3 Inflammasome: Mechanisms of Activation, Regulation, and Therapeutic Opportunities. [PDF]

MedComm (2020)
Zou C, Jiang S, Li H, Zhao K, Cao D, Yang G.   +5 more
europepmc   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Hypoglycemia secondary to type B insulin resistance syndrome. [PDF]

JCEM Case Rep
Naidoo P, Pirie FJ, Paruk IM.
europepmc   +1 more source

Nanomedicine for the Treatment of Pediatric Type 2 Diabetes: Progress, Challenges, and Translational Perspectives

Advanced Therapeutics, Volume 9, Issue 9, September 2026.
Overview of pharmaceutical nanocarriers in diabetes, illustrating applications of nanotechnology including enhanced drug and targeted drug delivery and nanosensors for glucose monitoring and diagnosis. ABSTRACT Pediatric type 2 diabetes mellitus (T2DM) is rapidly emerging as a critical global health concern, driven largely by rising childhood obesity ...
Nnamdi Ikemefuna Okafor, Bukosi Baloyi, Yahya E. Choonara   +2 more
wiley   +1 more source

Toxicological profile of anti-diabetic drugs and emerging measures to reduce the toxic burden. [PDF]

Toxicol Rep
Dugbartey GJ, Alornyo KK, Dapaa-Addo CO, Kwashie EK, Harley Y, Asiedu BN.   +5 more
europepmc   +1 more source

Type 5 Diabetes Mellitus: Pathophysiology, Clinical Phenotype, and Nutritional Management

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Type 5 Diabetes Mellitus (T5DM) is an emerging diabetes phenotype linked to chronic undernutrition. It predominantly affects young, lean individuals in low‐ and middle‐income countries. After its formal recognition by the International Diabetes Federation in 2025, T5DM resurfaced as a clinically relevant insulin‐deficient phenotype.
İrem Nur Şahin Anılgan, Aslıhan Atar‐Uğurlu   +1 more
wiley   +1 more source